428 results on '"Sharkey R"'
Search Results
52. P194 Why do lung cancer patients still die in hospital?
53. Effect of combination radioimmunotherapy (RAIT) and chemoimmunotherapy on therapeutic response and toxicity in xenograft models of human pancreatic carcinoma: First experimental studies.
54. Fractionated radioimmunotherapy (RAIT) for enhanced cumulative radiation delivery in the treatment of advanced pancreatic cancer (APC).
55. Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer
56. A novel bispecific antibody (bsMAb) construct for nuclear imaging of pancreatic cancer
57. Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
58. Evaluation of a novel MUC1 biomarker/target antigen for pancreatic cancer
59. Evaluation of a MAb-PAM4-defined MUC1 immunoassay as a potentially new diagnostic test for pancreatic cancer
60. Pretargeted radioimmunotherapy significantly improves the treatment of non-Hodgkin’s lymphoma in a nude mouse model
61. Recombinant bispecific antibodies (bsMAb) to carcinoembryonic antigen (CEA): Promising new agents for pretargeted radioimmunotherapy (RAIT) of solid tumors
62. Pretargeting for Cancer Radioimmunotherapy with Bispecific Antibodies: Role of the Bispecific Antibody's Valency for the Tumor Target Antigen
63. Authors’ reply
64. Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA × Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled Peptide
65. Anti-CEA Antibody Fragments Labeled with [18F]AlF for PET Imagingof CEA-Expressing Tumors.
66. Initial Clinical Experience with the CDR-grafted (humanized) LL2 anti-CD22 MAb against B-cell malignancies.
67. CD22 as target molecule for radioimmunodetection and radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic lecukemia and Waldenstromʼs macroglobulinemia
68. 99Tcm-LL1
69. Structure determination of N-linked oligosaccharides engineered at the CH1 domain of humanized LL2
70. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
71. EXERCISE SESSION RPE, HR AND LACTATE IN CARDIAC PATIENTS
72. Irish Thoracic Society
73. EXPERIMENTAL APPROACHES TO REDUCE DOSE-LIMITING RADIOANTIBODY-INDUCED MYELOTOXICITY
74. RADIOIMMUNOTHERAPY OF NON-HODGKINʼS LYMPHOMA WITH AN ANTI-CD22 MONOCLONAL ANTIBODY
75. USING CYTOKINE INTERVENTION TO OVERCOME DOSE-LIMITING, RADIOANTIBODY-INDUCED MYELOTOXICITY
76. TARGETING AND TREATMENT OF MEDULLARY THYROID CANCER WITH I-131-LABELED MURINE ANTI-CEA MONOCLONAL ANTIBODIES
77. ESTIMATES OF RED MARROW DOSE BY SACRAL SCINTIGRAPHY IN NHL PATIENTS WITH DIFFUSE BONE MARROW DISEASE
78. PROBLEMS AND PITFALLS OF 3-STEP AVIDIN-BIOTIN PRETARGETING
79. RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMAS WITH IODINE-131-LABELED LL2 MONOCLONAL ANTIBODY
80. PRECLINICAL AND CLINICAL EVALUATION OF A CDR-GRAFTED (HUMANIZED) ANTI-CARCINOEMBRYONIC ANTIGEN (CEA) MONOCLONAL ANTIBODY (MAb)
81. A PRECLINICAL COMPARISON OF TUMOR THERAPY AND MYELOTOXICITY FOR MU-9 ANTI-CSAp INTACT IgG AND FRAGMENTS LABELED WITH 1–131, Y-90 OR Re-188
82. TREATMENT OF NON-HODGKINʼS LYMPHOMA (NHL) WITH LL2, AN ANTI-CD 22 MONOCLONAL ANTIBODY
83. BIODISTRIBUTION AND PHARMACOKINETIC SCREENING OF THE MoAb PAM4 FOR IMMUNOSCINTIGRAPHY IN PATIENTS WITH PANCREATIC CANCER
84. Irish thoracic society
85. Aspects of the chemistry of calcium sulfate in coal ash
86. THREE APPROACHES TO REDUCE RADIOANTI-BODY-INDUCED MYELOSUPPRESSION
87. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors
88. Dose Escalation of Radioantibody in a Mouse Model With the Use of Recombinant Human Interleukin-1 and Granulocyte-Macrophage Colony-Stimulating Factor Intervention to Reduce Myelosuppression
89. TARGETING STUDIES IN NON-HODGKINʼS LYMPHOMA PATIENTS WITH A NEW Tc-99M-LABELED MONOCLONAL ANTIBODY IMAGING AGENT
90. TUMOR TARGETING IN PATIENTS WITH A SECOND GENERATION, HIGH-AFFINITY, ANTI- CARCINOEMBRYONIC ANTIGEN (CEA) MURINE MONOCLONAL ANTIBODY
91. DOSE ESCALATION OF RADIOANTIBODY IN A MOUSE MODEL USING RECOMBINANT IL-1 AND GM-CSF INTERVENTION TO REDUCE MYELOSUP-PRESSION
92. THE ANTITUMOR EFFECT AND THE SPECIFIC UPTAKE OF AN ANTI-CEA IMMUNOCONJUGATE (DOX-DEXTRAN-NP-4) IN IN VITRO AND IN VIVO
93. Fractionated radioimmunotherapy FOR PATIENTS WITH CHEMOTHERAPY-RESISTANT NON-HODGKINS LYMPHOMA (NHL)
94. Technetium-labeling of monoclonal antibodies with functionalized BATOs: 2. TcCl(DMG)3CPITC (CPITC=carboxyphenylisothiocyanate) labeling of B72.3 and NP-4 whole antibodies and NP-4 F(ab')2
95. TIME COURSE OF RECOVERY DURING CARDIAC REHABILITATION
96. Successful Radioimmuno-therapy for Lung Metastasis of Human Colonic Cancer in Nude Mice
97. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
98. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
99. In vivo stability and metabolism of 99Tcm-labelled anti-CD4 monoclonal antibodies and Fab' fragments.
100. 99Tcm-LL1.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.